Marit S.
- Country
- Norway
- Department
- Department of Nephrology
Research Overview
- Phase III Randomized Double‑Blind Placebo‑Controlled Trial of Elecoglipron (AZD5004) on Renal Decline and Mortality in Adults with Chronic Kidney Disease
- Evaluation of Zibotentan and Dapagliflozin Combination Versus Dapagliflozin Monotherapy in Chronic Kidney Disease with High Proteinuria: A Phase III Randomized Study
Data & Insights
Has run more than one trial at 22 of 261 partner sites.
Specializations
Nephrology
This investigator specializes in the study of chronic kidney disease, with particular emphasis on patients experiencing high proteinuria. Their research focuses on innovative therapeutic approaches for kidney function preservation.
- Kidney Disease Management
- Proteinuria Treatment
- Renal Function Protection
The investigator explores combination therapies aimed at slowing the progression of kidney dysfunction in affected patients.
Therapeutic Innovation
The investigator's work centers on evaluating novel therapeutic combinations, including the assessment of endothelin receptor antagonists and SGLT2 inhibitors in renal conditions.
- Combined Drug Therapy
- Novel Treatment Approaches
- Drug Efficacy Assessment
Their research encompasses the evaluation of treatment tolerability and safety profiles in renal patients.
Clinical Outcomes
The investigator focuses on measuring and analyzing kidney function preservation through various therapeutic interventions in chronic kidney disease patients.
- Disease Progression Analysis
- Treatment Response Assessment
- Patient Safety Monitoring
Their work involves comprehensive evaluation of therapeutic outcomes in renal disease management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.